KR102790656B1 - 아캄프로세이트의 스프링클 제형 - Google Patents

아캄프로세이트의 스프링클 제형 Download PDF

Info

Publication number
KR102790656B1
KR102790656B1 KR1020177033137A KR20177033137A KR102790656B1 KR 102790656 B1 KR102790656 B1 KR 102790656B1 KR 1020177033137 A KR1020177033137 A KR 1020177033137A KR 20177033137 A KR20177033137 A KR 20177033137A KR 102790656 B1 KR102790656 B1 KR 102790656B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical
disease
syndrome
sprinkle
acamprosate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177033137A
Other languages
English (en)
Korean (ko)
Other versions
KR20170142180A (ko
Inventor
스티븐 엘. 존스
케니스 지. 페이
바드리나스 알. 도니파시
샤이바라이 비. 무니안자나파
Original Assignee
컨플루언스 파마슈티컬스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 컨플루언스 파마슈티컬스, 엘엘씨 filed Critical 컨플루언스 파마슈티컬스, 엘엘씨
Publication of KR20170142180A publication Critical patent/KR20170142180A/ko
Application granted granted Critical
Publication of KR102790656B1 publication Critical patent/KR102790656B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020177033137A 2015-05-04 2016-05-04 아캄프로세이트의 스프링클 제형 Active KR102790656B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562156842P 2015-05-04 2015-05-04
US62/156,842 2015-05-04
US201562260161P 2015-11-25 2015-11-25
US62/260,161 2015-11-25
PCT/US2016/030725 WO2016179252A1 (en) 2015-05-04 2016-05-04 Sprinkle formulations of acamprosate

Publications (2)

Publication Number Publication Date
KR20170142180A KR20170142180A (ko) 2017-12-27
KR102790656B1 true KR102790656B1 (ko) 2025-04-02

Family

ID=57217823

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177033137A Active KR102790656B1 (ko) 2015-05-04 2016-05-04 아캄프로세이트의 스프링클 제형

Country Status (10)

Country Link
US (1) US10709668B2 (enExample)
EP (1) EP3291800A4 (enExample)
JP (2) JP7026347B2 (enExample)
KR (1) KR102790656B1 (enExample)
AU (1) AU2016258624B2 (enExample)
HK (1) HK1252003A1 (enExample)
IL (1) IL255343B2 (enExample)
SG (1) SG11201708393UA (enExample)
WO (1) WO2016179252A1 (enExample)
ZA (1) ZA201708037B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357469B2 (en) 2015-02-18 2019-07-23 Aston University Diagnostic assay and treatment for preeclampsia
US10709668B2 (en) 2015-05-04 2020-07-14 Confluence Pharmaceuticals, Llc Sprinkle formulations of acamprosate
HK1255584A1 (zh) * 2015-08-04 2019-08-23 Confluence Pharmaceuticals, Llc 使用阿坎酸及d-环丝胺酸的联合疗法
IL270654B2 (en) * 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof
EP3459528B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
WO2022058989A1 (en) * 2020-09-21 2022-03-24 Sun Pharmaceutical Industries Limited Multi-particulate pharmaceutical composition of quetiapine
WO2023048065A1 (ja) 2021-09-24 2023-03-30 住友ベークライト株式会社 脳波検出用電極、脳波測定装置及び脳波測定方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120077878A1 (en) 2010-09-28 2012-03-29 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
JP2014508812A (ja) * 2011-03-23 2014-04-10 アイアンショア ファーマシューティカルズ アンド ディベロップメント， インコーポレイテッド 注意欠陥障害の処置のための方法および組成物
WO2014197744A1 (en) * 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
AU765603C (en) 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
RU2375048C2 (ru) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
WO2009004082A2 (en) 2007-07-05 2009-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticonvulsive pharmaceutical compositions
HRP20150120T1 (hr) 2009-02-12 2015-05-08 Indiana University Research And Technology Corporation Materijal i metode za lijeäśenje poremeä†aja u razvoju ukljuäśujuä†i komorbidni i idiopatski autizam
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20110142889A1 (en) 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
WO2012117075A2 (en) 2011-03-01 2012-09-07 Pharnext Treatment of cerebral ischemia
JP5893135B2 (ja) 2011-06-28 2016-03-23 ビボゾーン インコーポレイテッド 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
SG11201606275WA (en) 2014-02-11 2016-08-30 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
US10709668B2 (en) 2015-05-04 2020-07-14 Confluence Pharmaceuticals, Llc Sprinkle formulations of acamprosate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120077878A1 (en) 2010-09-28 2012-03-29 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
JP2014508812A (ja) * 2011-03-23 2014-04-10 アイアンショア ファーマシューティカルズ アンド ディベロップメント， インコーポレイテッド 注意欠陥障害の処置のための方法および組成物
WO2014197744A1 (en) * 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same

Also Published As

Publication number Publication date
SG11201708393UA (en) 2017-11-29
IL255343B2 (en) 2024-10-01
AU2016258624B2 (en) 2021-07-29
US20190046458A1 (en) 2019-02-14
US10709668B2 (en) 2020-07-14
AU2016258624A1 (en) 2017-11-02
WO2016179252A1 (en) 2016-11-10
ZA201708037B (en) 2020-03-25
JP2021155434A (ja) 2021-10-07
JP2018515506A (ja) 2018-06-14
IL255343A0 (en) 2017-12-31
KR20170142180A (ko) 2017-12-27
EP3291800A1 (en) 2018-03-14
EP3291800A4 (en) 2018-09-26
JP7026347B2 (ja) 2022-02-28
HK1252003A1 (zh) 2019-05-10
IL255343B1 (en) 2024-06-01

Similar Documents

Publication Publication Date Title
KR102790656B1 (ko) 아캄프로세이트의 스프링클 제형
US20130224292A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
US20100047343A1 (en) Multiparticulate formulation having tramadol in immediate and controlled release form
CN101277684A (zh) 至少一种活性成分改善释放的微粒及含有该微粒的口服药物剂型
US20160101075A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
KR20170115036A (ko) 특히 주의력 결핍 장애의 치료를 위한 방법 및 조성물
JP7499539B2 (ja) ホモタウリンおよびその塩の製剤
KR101659983B1 (ko) 용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
CA3062834C (en) Formulations of homotaurines and salts thereof
KR101757147B1 (ko) 용융 압출된 방출 제어용 약학 조성물의 제조방법
Patel Formulation and evaluation of ranolazine sustained release tablets by hot melt coating technique
DIHYDROCHLORIDE Reg. No. 26106506
Patel Formulation Development and Optimization of Effervescent Systems for Histamine Antagonists
PHARMACEUTICS DEVELOPMENT OF FAST DISSOLVING TABLETS OF TORSEMIDE
HK1259508B (zh) 氘代多潘立酮组合物和用於治疗病症的方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171115

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210503

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230612

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240110

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230612

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20240110

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20231212

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210503

Comment text: Amendment to Specification, etc.

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240701

Patent event code: PE09021S01D

PX0701 Decision of registration after re-examination

Patent event date: 20250113

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250331

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250331

End annual number: 3

Start annual number: 1

PG1601 Publication of registration